| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695281 | Gynecologic Oncology | 2017 | 8 Pages |
Abstract
In vitro and in vivo experiments with 3Â + HER2/neu expressing EOC revealed limited anti-tumor activity of T or P. T-DM1 showed superior anti-tumor activity to T and P as single agents and as a combination. Our preclinical data support the design of clinical studies with T-DM1 for the treatment of chemotherapy-resistant EOC overexpressing HER2/neu.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Gary Altwerger, Jonathan D. Black, Katherine Dugan, Francesca Pettinella, Alice Masserdotti, Francesco Riccio, Anna Bianchi, Luca Zammataro, Christopher de Haydu, Natalia Buza, Pei Hui, Serena Wong,